12:00 AM
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Access Hybritech p2PSA assay regulatory update

Beckman Coulter Inc. said FDA approved its Access Hybritech p2PSA assay for use with its multivariate Prostate Health Index (phi) as an aid to distinguish prostate cancer from benign...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >